ORIGINAL ARTICLESAntitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell linesMuñoz, Miguel; Pérez, Ana; Rosso, Marisa; Zamarriego, Carmen; Rosso, RosarioAuthor Information Hospital Infantil Universitario Virgen del Rocío, Sevilla, Spain Sponsorship: This work was supported, in part, by Asociación de Padres de Niños Oncológicos de Andalucía y Extremadura (ANDEX). Correspondence and requests for reprints to Dr Miguel Muñoz, Hospital Infantil Virgen del Rocío, Unidad de Cuidados Intensivos Pediátricos, Av. Manuel Siurot s/n, 41013 – Sevilla, Spain Tel: +34 955012965; fax: +34 955012921; e-mail: [email protected] Received 21 August 2003 Accepted 5 February 2004 Melanoma Research: June 2004 - Volume 14 - Issue 3 - p 183-188 doi: 10.1097/01.cmr.0000129376.22141.a3 Buy Metrics Abstract Melanoma represents 1% of all cancers and accounts for approximately 65% of skin cancer deaths. At present, effective treatment does not exist. Substance P (SP) is a neuropeptide expressed in invasive malignant melanomas. We studied the in vitro growth inhibitory capacity of the potent and long-acting neurokinin-1 (NK1) receptor antagonist L-733 060 at concentration ranges of 2.5–20 μM, 10–30 μM and 20–50 μM in the melanoma cell lines COLO 858, MEL H0 and COLO 679, respectively. A Coulter counter was used to determine the number of viable cells, and the tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)2-(4-sulphophenyl)-2H-tetrazolium, inner salt (MTS) colorimetric method was used to evaluate cell proliferation. L-733 060 inhibited the growth of all three cell lines in a dose-dependent manner. The 50% inhibition concentration (IC50) was 8.7 μM at 48 h and 7.1 μM at 96 h for COLO 858, 27.5 μM at 24 h and 18.9 μM at 48 h for MEL H0, and 33.8 μM at 30 h and 31.5 μM at 72 h for COLO 679. These findings indicate that the NK1 receptor antagonist L-733 060 acts as an antitumoral agent. This action, shown here for the first time, suggests that the NK1 receptor antagonist L-733 060 could be a promising therapeutic drug in the treatment of the human melanoma. © 2004 Lippincott Williams & Wilkins, Inc.